Pfizer Inc
NYSE: PFE
$29.42
-$0.24 (-0.8%)
Closing Price on September 20, 2024
PFE Articles
General Electric saw its short interest drop sharply between the December 15 and December 31 settlement dates for the second period in a row. Meanwhile, short sellers piled on to Pfizer and...
Published:
Last Updated:
One good plan for stockholders who are seeing gains evaporate is to rotate to a more defensive sector. Large cap pharmaceutical stocks totally fit the bill.
Published:
Last Updated:
24/7 Wall Street has evaluated three major Dow components in the pharmaceutical industry and presented the bullish and bearish case for each in 2016.
Published:
Last Updated:
Dogs of the Dow is a dividend strategy for investors to buy what are either "cheap" or "beaten up" Dow stocks. Unfortunately, 2015 was an awful year for the members of the Dogs of the Dow.
Published:
Last Updated:
These companies all provide drugs and medical devices that help hundreds of thousands of people daily lead a better life. They make good sense for conservative portfolios looking for income and...
Published:
Last Updated:
The short interest data have been released for the December 15 settlement date, and for most of the selected pharmaceutical stocks short interest was up.
Published:
Last Updated:
General Electric saw its short interest drop sharply again between the November 30 and December 15 settlement dates.
Published:
Last Updated:
December 24, 2015: Markets opened mixed on Thursday after thin trading and little movement in both Europe and Asia. The report on U.S. jobless claims was better than expected, but weakness in some...
Published:
Last Updated:
24/7 Wall St. screened the Jefferies Franchise Picks list for the top-yielding stocks and found four with outstanding growth potential.
Published:
Last Updated:
December 21, 2015: Markets opened higher on Monday following a changing of the guard at the top of Spain’s government and new hope for another dose of government stimulus in China. A weaker...
Published:
Last Updated:
At the end of every year, myriad strategies are announced for the coming year. With investors continuing to love dividends, one strategy that is reviewed every year is the so-called Dogs of the Dow.
Published:
Last Updated:
Amgen is getting aggressive enough on its dividend payout that you might think the biotech giant is now just a Big Pharma stock.
Published:
Last Updated:
Merrill Lynch is among the first firms to present their top picks for 2016, a decidedly conservative set of picks, and probably with good reason.
Published:
Last Updated:
The November 30 short interest data have been compared with the previous figures, and for most of the selected pharmaceutical stocks, short interest was up.
Published:
Last Updated:
Brokerage firm Jefferies has released its top pharmaceutical picks for the coming year and what to expect.
Published:
Last Updated: